Voluntis is a French pioneer in prescription digital therapeutics (PDTs) — software-based medical treatments that have received regulatory clearance to treat specific diseases, complement drug therapies, or improve patient adherence to treatment protocols. Founded in 2001 in Paris, the company has survived long enough to see the market it anticipated finally emerge at scale, and has developed both the regulatory approvals and the clinical evidence base that distinguish genuine prescription digital therapeutics from the crowded wellness app market.
The company’s Theraxium platform supports the development, deployment, and management of prescription digital therapeutics — software applications that patients use between clinical encounters to manage symptoms, adjust dosing, or follow treatment protocols based on real-time data. Voluntis has received FDA 510(k) clearance for Oleena (oncology symptom management) and CE Mark for Diabeo (diabetes management with insulin dose titration), establishing regulatory credibility that distinguishes it from competitors in an FDA pre-submission stage.
France 2030 Funding and Projects
Voluntis participates in France 2030’s digital health and health innovation programs.
Oleena oncology digital therapeutic is Voluntis’s most commercially advanced product. Oleena is a prescription app for cancer patients undergoing chemotherapy that collects weekly patient-reported outcomes (fatigue, nausea, pain, appetite loss) and provides personalized responses — either alerting the clinical team to intervening early, providing self-management guidance, or adjusting supportive care recommendations. The FDA 510(k) clearance and multiple peer-reviewed clinical studies demonstrating improved quality of life and reduced emergency department visits make Oleena one of the better-validated oncology digital therapeutics globally. France 2030’s health innovation programs support clinical integration of digital therapeutics into French oncology protocols through the French National Cancer Institute (INCa) partnerships.
Diabeo insulin titration system for type 2 diabetes has demonstrated that algorithm-guided insulin dose adjustment reduces HbA1c (blood glucose control marker) more effectively than standard care in randomized controlled trials. France 2030’s diabetes prevention and management investments create market pull for digital therapeutics that improve glucose control while reducing clinician workload.
Theraxium platform is Voluntis’s strategic asset beyond individual products. The platform provides the technical infrastructure (patient apps, clinical dashboards, data security architecture, regulatory filing support, real-world evidence generation) for pharmaceutical companies and medical device manufacturers to develop their own prescription digital therapeutics. Partnerships with Sanofi and Roche for disease-specific digital therapeutic development demonstrate the platform’s commercial utility for large pharmaceutical players who want DTx capabilities without building the infrastructure from scratch.
France’s digital health regulatory framework — developed in part through Voluntis’s engagement with the HAS (Haute Autorité de Santé) and the new French regulatory framework for digital therapeutics — represents Voluntis’s policy contribution beyond individual products. France 2030’s digital health ambitions require regulatory clarity, and Voluntis has been a consistent advocate for a European digital therapeutics regulatory pathway.
Strategic Position
Voluntis’s competitive position in prescription digital therapeutics is that of a European pioneer with regulatory approvals competing against US-dominant startups: Pear Therapeutics (US, bankrupt 2023 — instructive cautionary tale), Welldoc (US, diabetes), Omada Health (US, pre-diabetes). The market is real but commercially challenging: healthcare payer reimbursement for PDTs is not yet systematically established in Europe, creating a commercial gap between clinical efficacy and market penetration.
The Pear Therapeutics bankruptcy in 2023 sent a warning signal through the DTx sector: clinical efficacy alone does not create sustainable business models. Reimbursement coverage, physician adoption, and patient engagement must all align for PDTs to generate sustainable revenue. Voluntis’s long experience in the sector (founded 2001, 23 years of navigating this landscape) provides survival skills that newer entrants lack.
Key Technology and Innovation
Voluntis’s Theraxium platform’s most technically sophisticated element is its rules-based clinical decision support system — translating validated clinical guidelines into patient-specific recommendations in real-time. Unlike AI-only approaches (where model explainability to clinicians is limited), Theraxium’s rule-based core can be audited and validated against clinical evidence, meeting the explainability requirements that medical device regulatory frameworks increasingly demand.
The company’s real-world evidence generation capabilities — using patient data collected through the apps to generate post-market clinical evidence — are increasingly valuable as France 2030’s health innovation programs require demonstration of clinical outcomes, not just regulatory approval.
Leadership
CEO Etienne Lacroix has led Voluntis through the difficult commercialization phase of a technology market that developed more slowly than early optimism predicted. His persistence through multiple market cycles — when PDT reimbursement seemed perpetually around the corner — reflects either genuine conviction or extraordinary patience, both of which are prerequisites for company-building in medtech timelines.
Investor Perspective
Voluntis has received Bpifrance investment and France 2030 health program support. The company is not publicly listed. Revenue from pharmaceutical partnerships (milestone payments, licensing fees) and direct DTx commercialization is growing but requires European insurance reimbursement frameworks to unlock full commercial scale. France 2030’s health innovation investments in French hospital digital health infrastructure create enabling conditions for DTx adoption without guaranteeing the commercial breakthrough.
Related Companies
- Sanofi — pharmaceutical partnership for DTx integration in drug therapy programs
- Servier — oncology-focused pharmaceutical potential DTx partner
- Wandercraft — fellow French medical robotics/technology company in the health innovation ecosystem
- bioMérieux — French health technology company in France 2030’s health ecosystem
- Volta Medical — fellow French medical device AI startup